HIGH confidence
Researched 2026-07-28 13:06 · profile: researcher
Programme Thesis
This programme funds a biotech startup developing RNAi therapeutics for CNS diseases using brain shuttle technology to cross the blood-brain barrier. It exists to support companies translating genetic medicine approaches into treatments for neurodegenerative disorders like Alzheimer's.
Selection Criteria
- Innovation and scientific merit of the platform technology (brain shuttle AOC delivery)
- Potential for clinical impact on genetically-driven neurological diseases
- Strength and track record of the founding team and scientific advisors
- Commercial viability and market opportunity in CNS therapeutics
- Investor confidence and syndicate quality (led by EQT Dementia Fund, age1)
Past Winners / Cohort Profiles
This is a Series A financing round for a single startup, Aerska, founded in 2025. No past cohort profiles or named winners beyond Aerska are available from this page.
Ideal Candidate Fingerprint
A biotech startup with a proprietary platform for CNS drug delivery, a strong scientific advisory board, and a clear path to clinical development for genetically-defined neurodegenerative diseases. The team should have deep expertise in RNA therapeutics, antibody-oligo conjugates, and blood-brain barrier biology.
Recommended Framing
Eniola should not apply for this funding as it is a venture capital round for a startup, not a grant or fellowship. However, his expertise in computational modeling of CNS drug delivery (ergofluids project on macromolecular transport through dense tissue) and addiction neuroscience could be framed as relevant foundational research for brain shuttle technologies. He could position himself as a potential future collaborator or consultant for such companies, but this specific programme is not a fit.
Watch Out
This is a Series A equity financing for a company, not a grant or fellowship for individual researchers. Eniola is an independent researcher, not a startup founder seeking venture capital. No eligibility for individual applicants.